drugset / Trial / NCT00162266

Abatacept With Methotrexate- Phase IIB

NCT00162266

Phase 2 Completed 524 enrolled Bristol-Myers Squibb
RandomizedParallel-groupQuadruple-blindTreatment

Summary

This study was conducted to assess the safety and tolerability of Abatacept combined with Methotrexate in participants with active rheumatoid arthritis (RA). The secondary objectives were to assess efficacy, pharmacodynamic marker activity, and immunogenicity of Abatacept combined with Methotrexate.

Timeline

Start
2000-10
Primary completion
2009-09
Completion
2009-09

Drugs

EvaluationDrugModalityDoseRoute
Subject Abatacept Other / unclassified 2 mg/kg Intravenous
Subject Abatacept Other / unclassified 10 mg/kg Intravenous

Indications